Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Computed Tomography | Research

A nomogram based on CT texture features to predict the response of patients with advanced pancreatic cancer treated with chemotherapy

Authors: Jingjing Li, Jiadi Du, Yuying Li, Mingzhu Meng, Junjie Hang, Haifeng Shi

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Objective

This study aimed to evaluate the predictive value of computed tomography (CT) texture features in the treatment response of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy.

Methods

This study enrolled 84 patients with APC treated with first-line chemotherapy and conducted texture analysis on primary pancreatic tumors. 59 patients and 25 were randomly assigned to the training and validation cohorts at a ratio of 7:3. The treatment response to chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1). The patients were divided into progressive and non-progressive groups. The least absolute shrinkage selection operator (LASSO) was applied for feature selection in the training cohort and a radiomics signature (RS) was calculated. A nomogram was developed based on a multivariate logistic regression model incorporating the RS and carbohydrate antigen 19-9 (CA19-9), and was internally validated using the C-index and calibration plot. We performed the decision curve analysis (DCA) and clinical impact curve analysis to reflect the clinical utility of the nomogram. The nomogram was further externally confirmed in the validation cohort.

Results

The multivariate logistic regression analysis indicated that the RS and CA19-9 were independent predictors (P < 0.05), and a trend was found for chemotherapy between progressive and non-progressive groups. The nomogram incorporating RS, CA19-9 and chemotherapy showed favorable discriminative ability in the training (C-index = 0.802) and validation (C-index = 0.920) cohorts. The nomogram demonstrated favorable clinical utility.

Conclusion

The RS of significant texture features was significantly associated with the early treatment effect of patients with APC treated with chemotherapy. Based on the RS, CA19-9 and chemotherapy, the nomogram provided a promising way to predict chemotherapeutic effects for APC patients.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.CrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
go back to reference Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol (London England). 2016;12(16):1929–46.CrossRef Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol (London England). 2016;12(16):1929–46.CrossRef
3.
go back to reference De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180.CrossRefPubMed De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180.CrossRefPubMed
4.
go back to reference Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2015;26(Suppl 5):v56–68.CrossRef Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2015;26(Suppl 5):v56–68.CrossRef
5.
go back to reference Tempero MA. NCCN Guidelines updates: pancreatic Cancer. J Natl Compr Cancer Network: JNCCN. 2019;17(55):603–5. Tempero MA. NCCN Guidelines updates: pancreatic Cancer. J Natl Compr Cancer Network: JNCCN. 2019;17(55):603–5.
6.
go back to reference Perera S, Jang GH, Wang Y, Kelly D, Allen M, Zhang A, Denroche RE, Dodd A, Ramotar S, Hutchinson S, et al. hENT1 expression predicts response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Clin cancer research: official J Am Association Cancer Res. 2022;28(23):5115–20.CrossRef Perera S, Jang GH, Wang Y, Kelly D, Allen M, Zhang A, Denroche RE, Dodd A, Ramotar S, Hutchinson S, et al. hENT1 expression predicts response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Clin cancer research: official J Am Association Cancer Res. 2022;28(23):5115–20.CrossRef
7.
go back to reference Facciorusso A, Stasi E, Di Maso M, Serviddio G, Ali Hussein MS, Muscatiello N. Endoscopic ultrasound-guided fine needle aspiration of pancreatic lesions with 22 versus 25 gauge needles: a meta-analysis. United Eur Gastroenterol J. 2017;5(6):846–53.CrossRef Facciorusso A, Stasi E, Di Maso M, Serviddio G, Ali Hussein MS, Muscatiello N. Endoscopic ultrasound-guided fine needle aspiration of pancreatic lesions with 22 versus 25 gauge needles: a meta-analysis. United Eur Gastroenterol J. 2017;5(6):846–53.CrossRef
8.
go back to reference Liang Z, Huang A, Wang L, Bi J, Kuang B, Xiao Y, Yu D, Hong M, Zhang T. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment. Aging. 2022;14(2):907–22.CrossRefPubMedPubMedCentral Liang Z, Huang A, Wang L, Bi J, Kuang B, Xiao Y, Yu D, Hong M, Zhang T. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment. Aging. 2022;14(2):907–22.CrossRefPubMedPubMedCentral
9.
go back to reference Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. Cancer J Clin. 2019;69(2):127–57.CrossRef Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. Cancer J Clin. 2019;69(2):127–57.CrossRef
11.
go back to reference Nasief H, Zheng C, Schott D, Hall W, Tsai S, Erickson B, Allen Li X. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ precision oncology. 2019;3:25.CrossRefPubMedPubMedCentral Nasief H, Zheng C, Schott D, Hall W, Tsai S, Erickson B, Allen Li X. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ precision oncology. 2019;3:25.CrossRefPubMedPubMedCentral
12.
go back to reference Simpson G, Spieler B, Dogan N, Portelance L, Mellon EA, Kwon D, Ford JC, Yang F. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: a pilot study. Med Phys. 2020;47(8):3682–90.CrossRefPubMed Simpson G, Spieler B, Dogan N, Portelance L, Mellon EA, Kwon D, Ford JC, Yang F. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: a pilot study. Med Phys. 2020;47(8):3682–90.CrossRefPubMed
13.
go back to reference Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 2017;8(1):127–38.CrossRefPubMedPubMedCentral Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 2017;8(1):127–38.CrossRefPubMedPubMedCentral
14.
go back to reference Nasief H, Hall W, Zheng C, Tsai S, Wang L, Erickson B, Li XA. Improving treatment response prediction for Chemoradiation Therapy of Pancreatic Cancer using a combination of Delta-Radiomics and the clinical biomarker CA19-9. Frontiers in oncology 2019, 9:1464. Nasief H, Hall W, Zheng C, Tsai S, Wang L, Erickson B, Li XA. Improving treatment response prediction for Chemoradiation Therapy of Pancreatic Cancer using a combination of Delta-Radiomics and the clinical biomarker CA19-9. Frontiers in oncology 2019, 9:1464.
15.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J cancer (Oxford England: 1990). 2009;45(2):228–47.CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J cancer (Oxford England: 1990). 2009;45(2):228–47.CrossRef
16.
go back to reference Yang F, Zhang J, Zhou L, Xia W, Zhang R, Wei H, Feng J, Zhao X, Jian J, Gao X, et al. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy. Eur Radiol. 2022;32(3):1538–47.CrossRefPubMed Yang F, Zhang J, Zhou L, Xia W, Zhang R, Wei H, Feng J, Zhao X, Jian J, Gao X, et al. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy. Eur Radiol. 2022;32(3):1538–47.CrossRefPubMed
17.
go back to reference Caruso D, Zerunian M, Ciolina M, de Santis D, Rengo M, Soomro MH, Giunta G, Conforto S, Schmid M, Neri E, et al. Haralick’s texture features for the prediction of response to therapy in colorectal cancer: a preliminary study. Radiol Med. 2018;123(3):161–7.CrossRefPubMed Caruso D, Zerunian M, Ciolina M, de Santis D, Rengo M, Soomro MH, Giunta G, Conforto S, Schmid M, Neri E, et al. Haralick’s texture features for the prediction of response to therapy in colorectal cancer: a preliminary study. Radiol Med. 2018;123(3):161–7.CrossRefPubMed
18.
go back to reference Park HJ, Kim JH, Choi SY, Lee ES, Park SJ, Byun JY, Choi BI. Prediction of therapeutic response of Hepatocellular Carcinoma to Transcatheter arterial chemoembolization based on Pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol. 2017;209(4):W211–20.CrossRefPubMed Park HJ, Kim JH, Choi SY, Lee ES, Park SJ, Byun JY, Choi BI. Prediction of therapeutic response of Hepatocellular Carcinoma to Transcatheter arterial chemoembolization based on Pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol. 2017;209(4):W211–20.CrossRefPubMed
19.
go back to reference Liang L, Ding Y, Yu Y, Liu K, Rao S, Ge Y, Zeng M. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study. BMC Med Imaging. 2021;21(1):75.CrossRefPubMedPubMedCentral Liang L, Ding Y, Yu Y, Liu K, Rao S, Ge Y, Zeng M. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study. BMC Med Imaging. 2021;21(1):75.CrossRefPubMedPubMedCentral
20.
go back to reference Tomaszewski MR, Latifi K, Boyer E, Palm RF, El Naqa I, Moros EG, Hoffe SE, Rosenberg SA, Frakes JM, Gillies RJ. Delta radiomics analysis of magnetic resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Radiation Oncol (London England). 2021;16(1):237.CrossRef Tomaszewski MR, Latifi K, Boyer E, Palm RF, El Naqa I, Moros EG, Hoffe SE, Rosenberg SA, Frakes JM, Gillies RJ. Delta radiomics analysis of magnetic resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Radiation Oncol (London England). 2021;16(1):237.CrossRef
21.
go back to reference Cheng SH, Cheng YJ, Jin ZY, Xue HD. Unresectable pancreatic ductal adenocarcinoma: role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019;113:188–97.CrossRefPubMed Cheng SH, Cheng YJ, Jin ZY, Xue HD. Unresectable pancreatic ductal adenocarcinoma: role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019;113:188–97.CrossRefPubMed
22.
go back to reference Salinas-Miranda E, Khalvati F, Namdar K, Deniffel D, Dong X, Abbas E, Wilson JM, O’Kane GM, Knox J, Gallinger S, et al. Validation of prognostic Radiomic features from resectable pancreatic ductal adenocarcinoma in patients with Advanced Disease undergoing chemotherapy. Volume 72. Canadian Association of Radiologists journal = Journal l’Association canadienne des radiologistes; 2021. pp. 605–13. 4. Salinas-Miranda E, Khalvati F, Namdar K, Deniffel D, Dong X, Abbas E, Wilson JM, O’Kane GM, Knox J, Gallinger S, et al. Validation of prognostic Radiomic features from resectable pancreatic ductal adenocarcinoma in patients with Advanced Disease undergoing chemotherapy. Volume 72. Canadian Association of Radiologists journal = Journal l’Association canadienne des radiologistes; 2021. pp. 605–13. 4.
23.
go back to reference Sheen H, Kim JS, Lee JK, Choi SY, Baek SY, Kim JY. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Abdom Radiol (New York). 2021;46(6):2839–49.CrossRef Sheen H, Kim JS, Lee JK, Choi SY, Baek SY, Kim JY. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Abdom Radiol (New York). 2021;46(6):2839–49.CrossRef
24.
go back to reference Bracci S, Dolciami M, Trobiani C, Izzo A, Pernazza A, D’Amati G, Manganaro L, Ricci P. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients. Radiol Med. 2021;126(11):1425–33.CrossRefPubMedPubMedCentral Bracci S, Dolciami M, Trobiani C, Izzo A, Pernazza A, D’Amati G, Manganaro L, Ricci P. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients. Radiol Med. 2021;126(11):1425–33.CrossRefPubMedPubMedCentral
25.
go back to reference Borhani AA, Dewan R, Furlan A, Seiser N, Zureikat AH, Singhi AD, Boone B, Bahary N, Hogg ME, Lotze M, et al. Assessment of response to Neoadjuvant Therapy using CT texture analysis in patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020;214(2):362–9.CrossRefPubMed Borhani AA, Dewan R, Furlan A, Seiser N, Zureikat AH, Singhi AD, Boone B, Bahary N, Hogg ME, Lotze M, et al. Assessment of response to Neoadjuvant Therapy using CT texture analysis in patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020;214(2):362–9.CrossRefPubMed
26.
go back to reference Neumann CCM, von Hörschelmann E, Reutzel-Selke A, Seidel E, Sauer IM, Pratschke J, Bahra M, Schmuck RB. Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. Hepatobiliary & pancreatic diseases international: HBPD INT. 2018;17(5):461–72.CrossRef Neumann CCM, von Hörschelmann E, Reutzel-Selke A, Seidel E, Sauer IM, Pratschke J, Bahra M, Schmuck RB. Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. Hepatobiliary & pancreatic diseases international: HBPD INT. 2018;17(5):461–72.CrossRef
27.
go back to reference Ye J, Ling J, Lv Y, Chen J, Cai J, Chen M. Pulmonary adenocarcinoma appearing as ground-glass opacity nodules identified using non-enhanced and contrast-enhanced CT texture analysis: a retrospective analysis. Experimental and therapeutic medicine. 2020;19(4):2483–90.PubMedPubMedCentral Ye J, Ling J, Lv Y, Chen J, Cai J, Chen M. Pulmonary adenocarcinoma appearing as ground-glass opacity nodules identified using non-enhanced and contrast-enhanced CT texture analysis: a retrospective analysis. Experimental and therapeutic medicine. 2020;19(4):2483–90.PubMedPubMedCentral
28.
go back to reference Li X, Ma Q, Xu Q, Duan W, Lei J, Wu E. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Design. 2012;18(17):2404–15.CrossRef Li X, Ma Q, Xu Q, Duan W, Lei J, Wu E. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Design. 2012;18(17):2404–15.CrossRef
29.
go back to reference Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12:171.CrossRefPubMedPubMedCentral Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12:171.CrossRefPubMedPubMedCentral
30.
go back to reference Hong S, Song KB, Hwang DW, Lee JH, Lee W, Jun E, Kwon J, Park Y, Park SY, Kim N, et al. Preoperative serum carbohydrate antigen 19 – 9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg. 2021;13(11):1423–35.CrossRefPubMedPubMedCentral Hong S, Song KB, Hwang DW, Lee JH, Lee W, Jun E, Kwon J, Park Y, Park SY, Kim N, et al. Preoperative serum carbohydrate antigen 19 – 9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg. 2021;13(11):1423–35.CrossRefPubMedPubMedCentral
31.
go back to reference Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Shiihara M, Yamamoto M. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scand J Gastroenterol. 2019;54(6):780–6.CrossRefPubMed Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Shiihara M, Yamamoto M. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scand J Gastroenterol. 2019;54(6):780–6.CrossRefPubMed
32.
go back to reference Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, et al. Factors Predicting Response, Perioperative Outcomes, and Survival following total neoadjuvant therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273(2):341–9.CrossRefPubMed Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, et al. Factors Predicting Response, Perioperative Outcomes, and Survival following total neoadjuvant therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273(2):341–9.CrossRefPubMed
33.
go back to reference Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Matsunaga Y, Shiihara M, Yamamoto M. Evaluation of early prognostic factors in patients with pancreatic ductal adenocarcinoma receiving Gemcitabine together with nab-paclitaxel. Cancer diagnosis & prognosis. 2021;1(5):399–409.CrossRef Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Matsunaga Y, Shiihara M, Yamamoto M. Evaluation of early prognostic factors in patients with pancreatic ductal adenocarcinoma receiving Gemcitabine together with nab-paclitaxel. Cancer diagnosis & prognosis. 2021;1(5):399–409.CrossRef
34.
go back to reference Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015, 107(2). Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015, 107(2).
35.
go back to reference Hang J, Xu K, Yin R, Shao Y, Liu M, Shi H, Wang X, Wu L. Role of CT texture features for predicting outcome of pancreatic cancer patients with liver metastases. J Cancer. 2021;12(8):2351–8.CrossRefPubMedPubMedCentral Hang J, Xu K, Yin R, Shao Y, Liu M, Shi H, Wang X, Wu L. Role of CT texture features for predicting outcome of pancreatic cancer patients with liver metastases. J Cancer. 2021;12(8):2351–8.CrossRefPubMedPubMedCentral
36.
go back to reference Shi H, Chen Z, Dong S, He R, Du Y, Qin Z, Zhou W. A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study. BMC Gastroenterol. 2022;22(1):279.CrossRefPubMedPubMedCentral Shi H, Chen Z, Dong S, He R, Du Y, Qin Z, Zhou W. A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study. BMC Gastroenterol. 2022;22(1):279.CrossRefPubMedPubMedCentral
37.
go back to reference Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRef Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRef
38.
go back to reference Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin oncology: official J Am Soc Clin Oncol. 2011;29(34):4548–54.CrossRef Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin oncology: official J Am Soc Clin Oncol. 2011;29(34):4548–54.CrossRef
39.
go back to reference Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–28.CrossRefPubMed Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–28.CrossRefPubMed
Metadata
Title
A nomogram based on CT texture features to predict the response of patients with advanced pancreatic cancer treated with chemotherapy
Authors
Jingjing Li
Jiadi Du
Yuying Li
Mingzhu Meng
Junjie Hang
Haifeng Shi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02902-4

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.